These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
99 related articles for article (PubMed ID: 6047292)
41. [Studies of the clinical and metabolic effects of a new anabolic steroid in oral administration: methyltrienolone. I. The behavior of the blood proteins and nitrogen balance]. Bellastella A; D'Alessandro B; Esposito V; Palumbo E; Pagano A; Martino Repole R Clin Ter; 1967 Apr; 41(1):73-7. PubMed ID: 5614301 [No Abstract] [Full Text] [Related]
43. Estrogen and progestogen therapy in postmenopausal women. Practice Committee of American Society for Reproductive Medicine Fertil Steril; 2008 Nov; 90(5 Suppl):S88-102. PubMed ID: 19007655 [TBL] [Abstract][Full Text] [Related]
44. [Mineral bone density in adolescents with hypogonadism: results of two hormonal replacement therapies]. Sodini F; Bertelloni S; Baroncelli GI; Basiloni V; Tacchini S; Saggese G Minerva Pediatr; 2001 Oct; 53(5):471-2. PubMed ID: 11668274 [No Abstract] [Full Text] [Related]
45. Exogenous progestagens and the human breast. Sitruk-Ware R; Plu-Bureau G Maturitas; 2004 Sep; 49(1):58-66. PubMed ID: 15351097 [TBL] [Abstract][Full Text] [Related]
46. Contents of HRT and mechanisms of action. Leake R J Epidemiol Biostat; 1999; 4(3):129-33; discussion 133-9. PubMed ID: 10695955 [TBL] [Abstract][Full Text] [Related]
48. Current status of endocrine therapy for advanced breast cancer. Bland KI Ann Surg Oncol; 1999 Dec; 6(8 Suppl):4S-7S. PubMed ID: 10619452 [No Abstract] [Full Text] [Related]
49. Hormone replacement therapy: estrogen after menopause. Gibaldi M Pharmacotherapy; 1996; 16(3):366-75. PubMed ID: 8726594 [No Abstract] [Full Text] [Related]
50. Suppression of cyclical ovarian function in the treatment of severe premenstrual syndrome. Studd J Menopause Int; 2007 Dec; 13(4):182-4. PubMed ID: 18088531 [No Abstract] [Full Text] [Related]
51. [Effect of an anabolic steroid on the cellular immunity and postoperative evaluation of uterine cervical cancer]. Ooshika Y; Umesaki N; Sako H; Kawabata M; Sugana T Gan To Kagaku Ryoho; 1984 Oct; 11(10):2177-84. PubMed ID: 6486833 [TBL] [Abstract][Full Text] [Related]
52. [Theory and practice of daily prescription and gynecologic consultation for treatment of hyperandrogenism. Indications and contraindications]. Vexiau P Contracept Fertil Sex; 1999 Dec; 27(12):816-22. PubMed ID: 10676037 [No Abstract] [Full Text] [Related]
53. The use of 1% pimecrolimus cream for the treatment of steroid-induced rosacea. Chu CY Br J Dermatol; 2005 Feb; 152(2):396-9. PubMed ID: 15727676 [No Abstract] [Full Text] [Related]
54. The controversy over estrogen replacement therapy: an update on clinical trials. Gnatuk CL Curr Womens Health Rep; 2002 Apr; 2(2):89-94. PubMed ID: 12116607 [TBL] [Abstract][Full Text] [Related]
55. Miscellaneous uses of anabolic steroids. Kopera H Wien Med Wochenschr; 1993; 143(14-15):397-8. PubMed ID: 7504853 [TBL] [Abstract][Full Text] [Related]
56. Clinical use of progestins in the menopausal patient: dosage and duration. Gambrell RD J Reprod Med; 1982 Aug; 27(8 Suppl):531-8. PubMed ID: 7131446 [TBL] [Abstract][Full Text] [Related]
57. Combined esterified estrogens and methyltestosterone versus esterified estrogens alone in the treatment of loss of sexual interest in surgically menopausal women. Warnock JK; Swanson SG; Borel RW; Zipfel LM; Brennan JJ; Menopause; 2005; 12(4):374-84. PubMed ID: 16037752 [TBL] [Abstract][Full Text] [Related]
58. Chemoprevention of breast cancer. Bonte J Eur J Cancer Prev; 1993 Nov; 2 Suppl 3():141-5. PubMed ID: 8298444 [No Abstract] [Full Text] [Related]